64695-06-3

Basic information

• Product Name: ARG-PRO-PRO-GLY-PHE-SER-PRO-LEU
• Synonyms: leu(8)-des-arg(9)-bradykini;H-ARG-PRO-PRO-GLY-PHE-SER-PRO-LEU-OH;(DES-ARG9,LEU8)-BRADYKININ;BRADYKININ DES ARG9, LEU8;ARG-PRO-PRO-GLY-PHE-SER-PRO-LEU;[LEU8, DES-ARG9]-BRADYKININ;RPPGFSPL;bradykinin, Leu(8)-des-Arg(9)-
• CAS NO: 64695-06-3
• Molecular Formula: C₄₁H₆₃N₁₁O₁₀
• Molecular Weight: 870.01
• Product Categories: peptide
• Mol File: 64695-06-3.mol
• Article Data: 1

Chemical Properties

• Appearance: White powder
• Density: 1.46 g/cm³
• Refractive Index: 1.672
• Storage Temp.: -15°C
• CAS DataBase Reference: ARG-PRO-PRO-GLY-PHE-SER-PRO-LEU(CAS DataBase Reference)
• NIST Chemistry Reference: ARG-PRO-PRO-GLY-PHE-SER-PRO-LEU(64695-06-3)
• EPA Substance Registry System: ARG-PRO-PRO-GLY-PHE-SER-PRO-LEU(64695-06-3)

Safety Data

• Hazardous Substances Data: 64695-06-3(Hazardous Substances Data)

Usage

General Description

The chemical ARG-PRO-PRO-GLY-PHE-SER-PRO-LEU is a peptide composed of the amino acids arginine (ARG), proline (PRO), glycine (GLY), phenylalanine (PHE), serine (SER), and leucine (LEU). This sequence has potential physiological effects in the body, as each amino acid has specific functions and interactions within biological processes. For example, arginine is involved in the production of nitric oxide, which helps regulate blood flow, while proline plays a role in collagen formation and wound healing. Overall, the combination of these amino acids in ARG-PRO-PRO-GLY-PHE-SER-PRO-LEU has the potential to impact various physiological and biochemical pathways within the body.

InChI:InChI=1/C41H63N11O10/c1-24(2)20-28(40(61)62)48-36(57)31-14-8-17-50(31)38(59)29(23-53)49-34(55)27(21-25-10-4-3-5-11-25)47-33(54)22-46-35(56)30-13-7-18-51(30)39(60)32-15-9-19-52(32)37(58)26(42)12-6-16-45-41(43)44/h3-5,10-11,24,26-32,53H,6-9,12-23,42H2,1-2H3,(H,46,56)(H,47,54)(H,48,57)(H,49,55)(H,61,62)(H4,43,44,45)/t26-,27-,28-,29-,30-,31-,32-/m0/s1

Upstream product

• 29022-11-5 N-(fluoren-9-ylmethoxycarbonyl)glycine 
• 35661-60-0 Fmoc-Leu-OH 
• 71989-31-6 Fmoc-Pro-OH 
• 35661-40-6 N-Fmoc L-Phe 
• 73724-45-5 N-(9H-fluoren-9-ylmethoxycarbonyl)-L-serine 
• 91000-69-0 Fmoc-L-Arg-OH 

Relevant articles and documents

Discovery of amphipathic dynorphin A analogues to inhibit the neuroexcitatory effects of dynorphin A through bradykinin receptors in the spinal cord

We hypothesized that under chronic pain conditions, up-regulated dynorphin A (Dyn A) interacts with bradykinin receptors (BRs) in the spinal cord to promote hyperalgesia through an excitatory effect, which is opposite to the well-known inhibitory effect of opioid receptors. Considering the structural dissimilarity between Dyn A and endogenous BR ligands, bradykinin (BK) and kallidin (KD), this interaction could not be predicted, but it allowed us to discover a potential neuroexcitatory target. Well-known BR ligands, BK, [des-Arg10, Leu9]-kallidin (DALKD), and HOE140 showed different binding profiles at rat brain BRs than that previously reported. These results suggest that neuronal BRs in the rat central nervous system (CNS) may be pharmacologically distinct from those previously defined in non-neuronal tissues. Systematic structure-activity relationship (SAR) study at the rat brain BRs was performed, and as a result, a new key structural feature of Dyn A for BR recognition was identified: amphipathicity. NMR studies of two lead ligands, Dyn A-(4-11) 7 and [des-Arg7]-Dyn A-(4-11) 14, which showed the same high binding affinity, confirmed that the Arg residue in position 7, which is known to be crucial for Dyn As biological activity, is not necessary, and that a type I B-turn structure at the C-terminal part of both ligands plays an important role in retaining good binding affinities at the BRs. Our lead ligand 14 blocked Dyn A-(2-13) 10-induced hyperalgesic effects and motor impairment in in vivo assays using na?ve rats. In a model of peripheral neuropathy, intrathecal (i.th.) administration of ligand 14 reversed thermal hyperalgesia and mechanical hypersensitivity in a dose-dependent manner in nerve-injured rats. Thus, ligand 14 may inhibit abnormal pain states by blocking the neuroexcitatory effects of enhanced levels of Dyn A, which are likely to be mediated by BRs in the spinal cord.